KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Restructuring Costs (2022 - 2024)

Neogenomics' Restructuring Costs history spans 3 years, with the latest figure at $2.4 million for Q1 2024.

  • For Q1 2024, Restructuring Costs fell 48.8% year-over-year to $2.4 million; the TTM value through Mar 2024 reached $8.8 million, down 4.33%, while the annual FY2024 figure was $6.7 million, 39.95% down from the prior year.
  • Restructuring Costs reached $2.4 million in Q1 2024 per NEO's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $4.7 million in Q1 2023 to a low of $1.2 million in Q4 2023.
  • Average Restructuring Costs over 3 years is $3.0 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Restructuring Costs: tumbled 73.32% in 2023, then plummeted 48.8% in 2024.
  • A 3-year view of Restructuring Costs shows it stood at $4.5 million in 2022, then crashed by 73.32% to $1.2 million in 2023, then surged by 99.0% to $2.4 million in 2024.
  • Per Business Quant, the three most recent readings for NEO's Restructuring Costs are $2.4 million (Q1 2024), $1.2 million (Q4 2023), and $2.1 million (Q3 2023).